Introduction {#S1}
============

Cellular processes are usually dependent on network dynamics and interactions of macromolecular protein complexes. Identification of interactomes of proteins and consequently connecting molecular processes are important steps for understanding complex functions such as cell signaling and receptor trafficking. Here we focused on the identification of the interactome of the CB2, which belongs to the potentially therapeutic GPCRs. GPCRs are implicated in the pathophysiology of numerous human diseases like hypertension ([@B4]), Parkinson's disease ([@B54]; [@B23]), various cancers ([@B38]; [@B69]), and infectious diseases ([@B27]), thus reflecting their immense therapeutic and clinical relevance. Due to difficulties in preserving the complex three-dimensional GPCR structure during receptor solubilization the identification of their interacting partners is demanding ([@B15]). In this context methods of tandem AP-MS and MYTH approaches have been optimized for robustness and reproducibility to obtain high-confidence protein complex information and to systematically find interactions of full-length integral membrane receptors ([@B15]; [@B24]; [@B62]). These methods have indeed been successfully used for studies on clinically relevant GPCRs such as serotonin 5-HT4d, adenosine ADORA2A receptors ([@B62]), and CB1 ([@B45]) but not for CB2.

The CB2 receptor has been shown to contribute to various pathological states in animal models especially in neurodegenerative, immunological, inflammatory, cardiovascular, hepatic, and bone disorders ([@B53]). CB2 acts as a modulator of immune suppression, induction of apoptosis, and cell migration ([@B3]). In pathophysiological conditions CB2 is often upregulated in immune cells, where it inhibits proinflammatory cytokine production ([@B63]). The pharmacological modulation of the transcription factor PPARalpha represents an important mechanism through which CB2 expression could be regulated ([@B25]). Of note, CB2 receptors are involved in the regulation of co-stimulatory factors, such as LPS and TNF-alpha, which signal via distinct membrane receptors ([@B65]). Hence, it is of interest to identify interactors of CB2 that might act as signaling hubs for the crosstalk of different signaling events or that regulate the trafficking and degradation of the receptor.

By an AP-MS approach we have now identified p62 (also named sequestosome 1, SQSTM1) as an interacting partner of CB2 receptor. The scaffold protein p62 contains various domains that modulate protein--protein interactions; p62, e.g., associates with TRAF6 and with the death-domain kinase RIP1 and regulates NF-κB (nuclear factor- light-chain-enhancer of activated B cells) and MAP kinase signaling downstream of the TNF receptor, RANK receptor and nerve growth factor receptor ([@B47]). Mutations in p62 are associated with neurodegenerative diseases and with PDB. The latter is characterized by increased bone remodeling in focal areas leading to bone pain, deformities and fractures ([@B39]; [@B61]). A P392L exchange found in the UBA of the C-terminal part of p62 protein is a prominent mutation present in patients with PDB and with amyotrophic lateral sclerosis and/or frontotemporal dementia ([@B39]; [@B8]; [@B47]; [@B19]). This UBA domain is also of importance for the interaction of p62 with polyubiquitinated proteins, destined for degradation by autophagy ([@B46]). Through its interaction with LC3B p62 recruits ubiquitinated cargo proteins to the autophagosomal degradation pathway ([@B52]). Defects in autophagy lead to an accumulation of p62 ([@B35]). P62 aggregates are highly accumulated in neurons and glial cells in patients with neurodegenerative diseases ([@B60]; [@B1]). Interestingly, in a number of neurodegenerative disorders a CB2 upregulation especially in microglial cells has been described and neuroprotective effects of CB2 ligands were shown ([@B7]).

In summary, with a systematic unbiased approach we identified the CB2 interactome. Our data will serve in future studies to decipher cannabinoid receptor trafficking and signaling complexes and receptor homeostasis. We could furthermore validate our approach by confirming an interaction of CB2 with p62. Interestingly, it has been shown that the dysfunction of both proteins alone is critically involved in related disorders affecting brain and bone ([@B51]; [@B17]; [@B58]), so that future studies will have to analyze the exact mechanism of this interaction and investigate its role in pathophysiological conditions.

Materials and Methods {#S2}
=====================

Antibodies and Reagents {#S2.SS1}
-----------------------

The following antibodies and chemicals were used: Rabbit anti-p62 (\#P0067, Sigma), mouse anti-CB2 (\#H00001269-M01, Abnova), secondary antibodies; Alexa Fluor^®^488 goat anti-mouse (\#A21202, Thermo Fisher Scientific), Alexa Fluor^®^649 goat anti-rabbit (\#111-496-144, JacksonImmuno Research), rabbit anti-FLAG (\#F7425, Sigma). Lectin WGA conjugated with Texas Red^®^-X (\#W7024, Thermo Fisher Scientific) HU-210 from Tocris (CAS No. 112830-95-2), poly-[L]{.smallcaps}-Lysine (\#P6282-5mg, Sigma), bovine serum albumin (\#A9418, Sigma), Triton X-100 (\#A4975, AppliChem), ProLong^®^ Gold antifade reagent with DAPI (\#P36935, Thermo Fisher Scientific), HBSS (\#H6648, Sigma).

Plasmids and Cell Culture {#S2.SS2}
-------------------------

Human HEK293 cells (obtained from ATCC) were cultured in Dulbecco's modified Eagle's medium (Thermo Fisher Scientific) supplemented with 10% FBS, penicillin (50 units/ml), and streptomycin (50 μg/ml) at 37°C, 5% CO~2~. Transient transfections were performed with Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's protocol.

Flag-p62 and CB2 expression vectors were generated by inserting human cDNA in-frame into EcoRI and XhoI sites into the pcDNA3.1 vector (Thermo Fisher Scientific). The deletion constructs for p62 and CB2 were generated by site-directed mutagenesis using the QuikChange site directed mutagenesis kit (\#200523, Agilent) according to the manufacturer's protocol. The ΔC-CB2 construct was generated by PCR amplification introducing a stop codon after the amino acid position 300 of human CB2 protein sequence. CB2 deletion constructs of intracellular loops (Δi) and p62 deletion constructs via XL II Gold Site-Directed Mutagenesis Kit (\#200521, Agilent) were generated using following primer pairs ([Table 1](#T1){ref-type="table"}).

###### 

Sequences of primer pairs used for the generation of CB2 deletion constructs of intracellular loops (Δi) and p62 deletion constructs.

  **Flag-plasmids**       **Forward primer (5′--3′)**            **Reverse primer (5′--3′)**
  ----------------------- -------------------------------------- --------------------------------------
  Δi1-CB2                 GTGCTCTATCTGATCCTGCTGTTCATTGGCAGCTTG   CAAGCTGCCAATGAACAGCAGGATCAGATAGAGCAC
  Δi2-CB2                 CCTCCTGCTGACCGCCATTGCACTGGTGA          TCACCAGTGCAATGGCGGTCAGCAGGAGG
  Δi[3-CB2]{.smallcaps}   GGGCATGTTCTCTGGACCCTAGGGCTAGTG         CACTAGCCCTAGGGTCCAGAGAACATGCCC
  p62-ΔZZ122-167          AGGGGCTGGGGAACATGTTGCGGGGC             GCCCCGCAACATGTTCCCCAGCCCCT
  P62-ΔPEST266-294        CCCACCCGGCTTTCTTTTCCCTCCGTGCT          AGCACGGAGGGAAAAGAAAGCCGGGTGGG
  P62-ΔUBA389-434         CACATCTCCCGCCAAAGCATCCCCCGCC           GGCGGGGGATGCTTTGGCGGGAGATGTG

Bait Cloning and Stable Cell Line (Dualsystems Biotech AG) {#S2.SS3}
----------------------------------------------------------

The human open reading frame of the CB2 receptor (NM_001841.3; corresponding to NP_001832) was inserted into the bait vector pN-TGSH (Dualsystems). Bait expression construct pN-TGSH/CB2 with N-terminal Strep-HA fusion was used for the generation of a stable cell line using the FRT-HEK293 cells (Thermo Fisher Scientific) containing a single genomic FRT site supporting the rapid generation of bait-expressing cell lines by Flp-mediated recombination ([@B50]; [@B24]). Stable cell line HEK293/CB2 was cultured in complete medium (D-MEM (high glucose), 10% FBS, 2 mM [L]{.smallcaps}-glutamine, 100 ug/ml Hygromycin) at 37°C, 5% CO~2~.

Affinity Purification and Mass Spectrometric Analysis {#S2.SS4}
-----------------------------------------------------

The Dualsystems CaptiVate approach including LC--MS/MS analysis and peptide assignment were described previously in detail ([@B24]). For the analysis of stable cell line and bait expression protein extraction was performed with 0.5% DDM containing affinity purification lysis buffer (Dualsystems) followed by a 12% SDS-PAGE and Western blotting. A mouse monoclonal anti-HA antibody was used for bait detection. Calculated mass of the fusion protein was 50 kDa. Pulldown was performed with CB2 expressing and non-expressing control Flp-In HEK293 cell lysates and 100 μl Strep-Tactin Sepharose. Affinity purification and mass spectrometric analysis of Strep-HA CB2 was performed in three biological replicates for quantitative mass spectrometric analysis and monitored by Western blotting. The samples were analyzed on a Thermo LTQ Orbitrap XL spectrometer using a C18 column, ESI and a 60 min gradient. The variation of the biological replicates of untransfected (replicates 1--3 control cells) or Strep-HA CB2 expressing HEK293 cells (replicates 1--3 CB2 cells) was below 10% that was calculated as Pearson's correlation coefficient of variation (r) by GraphPad Prism software. All steps of the CaptiVate approach were done by Dualsystems Biotech AG (Schlieren, Switzerland) and were described in details previously ([@B24]). Results and experimental parameters for mass spectrometric analysis and protein identification are given in the [Supplementary Tables 1--6](#TS1){ref-type="supplementary-material"}.

Background Subtraction {#S2.SS5}
----------------------

To define the background the affinity purified sample without CB2 (control sample) was used as a negative control experiment. Such a negative control should reproduce a maximum of unspecific bindings that can be subtracted to identify the interacting portion of the obtained peptides. Therefore, we calculated log2 of intensity of probe samples versus control samples (column B) with the range of \>1,000 and analyzed the normal distribution (Gauss curve) by counting and distributing them on a bin histogram. For the whole range of log2 values defined bins with increments of 0.2 were set. The adjusted values were multiplicated by total number of values in column B (used for frequency distribution calculation). The threshold was set to 10% of the maximal peak height at 5.3152.

Protein Interaction Analysis {#S2.SS6}
----------------------------

All identified proteins that were detected by more than one unique peptide were used for the generation of an interaction network using the STRING program on <https://string-db.org/> ([@B64]). The top five results of GO analysis categorized into BP, MF, and CC were also obtained by STRING database. Further GO annotations were performed by the DAVID Bioinformatics Database^[1](#footnote1){ref-type="fn"}^ ([@B29], [@B30]). The enrichment score represents the overall enrichment for a group based on the EASE Score of each term members. EASE Score is a modified Fisher Exact *p*-Value, for gene-enrichment analysis. GraphPad PRISM software (Version 7) was used for linear regression and Gaussian distribution.

Immunocytochemistry {#S2.SS7}
-------------------

HEK293 cells were plated on poly-[L]{.smallcaps}-Lysine coated glass cover slips and transfected with CB2-plasmid (2 μg) with Lipofectamine 2000. After 24 h of transfection cells were washed with HBSS and fixed with Rotifix (4% PFA/PBS) for 15 min at 37°C. After washing the cells were stained with the lectin WGA conjugated with texas red (Texas Red^®^-X conjugate of WGA 1:200, 15 min, RT) which binds to sialic acid and *N*-acetylglucosaminyl residues that is used as a marker for plasma membranes before permeabilization. After three washing steps cells were permeabilized with 2% Triton X-100 in 2% BSA in PBS for 45 min at RT on a shaker followed by an incubation with primary antibodies for CB2 (Abnova, 1:300) and p62 (Sigma, 1:300) overnight at 4°C in 2% BSA-PBS. Secondary antibodies (1:1,000 in 2% BSA and 1% normal horse serum in PBS) were incubated for 1 h at RT, cells were washed and mounted with ProLong^®^ Gold antifade reagent with DAPI.

Imaging and 3D Reconstruction Modeling {#S2.SS8}
--------------------------------------

Four colors images were acquired by mean of a confocal laser scan microscope, i.e., Leica TCS SP5. As excitation four laser lines, 405, 488, 561, 633 nm were employed. For excitation and for detection of the fluorescence signal a 63x NA 1.4 oil objective lens was used. An AOBS separated the detected light from the excitation signal. The fluorescence signal, after being spectrally separated, was directed to a HyD. An estimation of the p62 co-localization with CB2 was performed by using the Manders coefficient. Therefore, we imaged a field of view including approximately 10 cells from eight coverslips in an area of approximately 125 μm^2^ with a pixel size of approximately 81 nm and a z-stack spacing of 300 nm. The laser light and detector gain were set in a way that the saturation of the detected signal was avoided. After repetitive measurements the background was estimated to be equal to 10/5% of the peak signal for p62/CB2 channels respectively and was subtracted in each channel accordingly. All the post-processing analysis and evaluation were performed with the software Bitplane Imaris. The mean values obtained per image were used for the calculation of mean ± SD. In all the three-dimensional acquisitions the lateral (xy) pixel size was set to be 100 nm (x, y) and the transversal pixel size was set to be 300 nm, i.e., the distance between image planes within a stack (z). Laser intensities and detection gain were to be the same in order to perform comparative studies between the acquired images. The software Bitplane Imaris was used to visualize and study the confocal pictures. As preliminary data visualization the signal offset was determined and subtracted from each image channel. Afterward, a segmentation algorithm was used for visualizing the spatial distribution of the samples under investigation. This algorithm uses a variable intensity threshold based on the local variation of signal to offset ratio to isolate a structure and it was the ideal choice for analyzing objects that, like the ones under investigation, are not continuous within the image volume. Finally, all signal above the local threshold belongs to the structure and all signal under the threshold are set to zero. For each fluorophore a threshold value was determined that represented an optimal coverage of the raw images. Segmented images were than displayed and image snapshots were taken at different visualization angles as well as different zoom factors.

Stimulation of HEK293 Cells With CB2- Synthetic Cannabinoids {#S2.SS9}
------------------------------------------------------------

Transiently transfected HEK293 cells were stimulated with 100 nM HU-210 for 10 min about 24 h after transfection. Therefore, medium was aspirated and 500 μl of DMEM containing 10% FCS and synthetic cannabinoid or solvent control (ethanol), respectively, were added. HEK293 cells were incubated in 5% CO~2~ atmosphere at 37°C. Afterward, cell lysates were prepared as described in the following paragraphs.

Co-immunoprecipitation {#S2.SS10}
----------------------

To immunoprecipitate Flag-tagged proteins transiently transfected HEK293 cells in 6-well cell culture plate were used. About 24 h after transfection the medium of the HEK293 cells was aspirated and the cells were washed with 800 μl ice-cold PBS from the plate and transferred to a 1.5 ml reaction vessel. After a centrifugation step at 8.000 × *g* at RT for 2 min supernatant was removed and the cell pellet was resuspended in 120 μl 0.2% DDM lysis buffer. Cell suspension was incubated by end-over-end rotation at 4°C for 30 min and centrifuged at 16.200 × *g* at 4°C for 15 min to remove cell debris. Cell lysates could be directly used for immunoprecipitation or stored at −80°C. 20 μl of cell lysates were used as input control, to this end it was mixed with 5 μl SDS loading buffer and stored on ice until SDS-PAGE. For each immunoprecipitation sample 8 μl anti-Flag^®^ M2 affinity gel was prepared. For that purpose, the whole volume of anti-Flag^®^ M2 affinity gel was washed three times with about 500 μl 0.2% DDM lysis buffer. For each sample 100 μl 0.2% DDM lysis buffer was added to the washed anti-Flag^®^ M2 affinity gel. The remaining cell lysate was diluted with 200 μl 0.2% DDM lysis buffer and 100 μl anti-Flag^®^ M2 affinity gel were added and incubated by end-over-end rotation at 4°C for 1 h. The immunoprecipitates were washed three times with 500 μl lysis buffer containing 0.2% DDM and one time with 500 μl ice-cold PBS. Remaining supernatant was removed with a syringe and cannula. After washing 18 μl SDS loading buffer were added to the immunoprecipitates which were incubated at 70°C for 10 min. The input samples were not heated. Immunoprecipitates and input control samples were analyzed by SDS-PAGE and Western blotting.

Western Blotting Analysis {#S2.SS11}
-------------------------

HEK293 cell lysates were mixed with 6x Laemmli buffer \[100 mM Tris-HCl (pH 6.8), 4% SDS, 60% glycerol, 0.2% bromophenol blue, and 10 mM DTT in dH~2~O\]. Proteins of the cell lysate were separated via SDS-PAGE with 12% gels and transferred to Amersham Hybond ECL nitrocellulose membrane (\#RPN2032D, GE Healthcare, United Kingdom). After blocking with 5% skimmed milk powder in TBS-T (150 mM NaCl, 10 mM Tris and 0.025% Tween^®^ 20 in dH~2~O), the membrane was incubated with specific primary antibodies in TBS-T or blocking buffer over night at 4°C. Afterward, fluorescence dye-conjugated or HRP-coupled secondary antibodies were incubated for 1 h at RT. After washing the proteins were detected with the two-channel IR direct detection imaging system from Odyssey LI-COR, United States, or by chemiluminescence. Signal quantifications were done using the Image Studio Software 5.2.5 of LI-COR Bioscience.

Results {#S3}
=======

Analysis of Affinity Purified CB2 Receptor Complexes {#S3.SS1}
----------------------------------------------------

Most biochemical investigations of GPCRs including CB2 are methodologically challenging due to their topology as multiple transmembrane proteins, that is vulnerable to common extraction procedures. We therefore used a method especially applicable for membrane receptors combining systematic affinity purification and mass spectrometric analysis to identify CB2 putative interaction partners ([Figure 1A](#F1){ref-type="fig"}, CaptiVate Dualsystems, performed by Dualsystems Biotech AG, Switzerland) ([@B24]). Due to the lack of specific and reliable antibodies for a detection of endogenous CB2 receptors ([@B9]), we were restricted in our studies to use heterologous expression systems. To this aim the bait CB2 was sub-cloned and stably expressed in HEK293 Flp-In cells. Affinity purification and quantitative mass spectrometric analysis (LC--MS/MS) of Strep-HA CB2 were performed in three biological replicates. The samples analyzed showed a variation below 10% of the biological replicates of untransfected or Strep-HA CB2 expressing HEK293 cells ([Supplementary Figure 1](#FS1){ref-type="supplementary-material"}).

![**(A)** Flow chart of CaptiVate screening procedure. The bait CB2 was amplified and sub-cloned into the expression vector pN-TGSH (Dualsystems). The bait sequence was verified by sequencing. For constitutive expression, the bait was transfected into HEK293 Flp-In cells and selected for stable integration. Bait expression and solubility was monitored by immunoblotting using anti-HA antibodies. The expression level was compared to an internal standard and judged suitable for affinity purification and mass spectrometric analysis. **(B)** Background filtering of CB2 affinity purification: histogram of enrichment factors (CB2/control) of identifications to determine threshold of enrichment for specific interactors. Red area represents Gaussian distribution of unspecific interactors, yellow area is in the border and in the green area are the specific interactors (threshold as 10% of maximum peak height).](fnmol-12-00224-g001){#F1}

Indeed, a total of 39.2% of the CB2 protein sequence was covered by mass spectrometric data. In total 698 proteins were identified. As expected for a GPCR guanine-nucleotide-binding protein G subunits alpha GNAI3 and GNAS1 have each been identified by one unique peptide. After subtraction of background interactions ([Figure 1B](#F1){ref-type="fig"}) and protein frequency library assessment ([@B24]) we could identify 83 putative interactors that were classified by the identification of minimally two unique peptides as highly probable interactors ([Table 2](#T2){ref-type="table"}).

###### 

CB2 interactors in HEK293 cells.

  **Entry**   **Entry name**   **Protein names**                                                                        **Unique**   **Sequence**   **Molecular**   **Ratio**
  ----------- ---------------- ---------------------------------------------------------------------------------------- ------------ -------------- --------------- -------------
  P34972      CNR2_HUMAN       Cannabinoid receptor 2                                                                   16           39.2           39.68           845.0
  Q15392      DHC24_HUMAN      Delta(24)-sterol reductase                                                               2            5.4            60.101          Only in CB2
  Q9Y394      DHRS7_HUMAN      Dehydrogenase/reductase SDR family member 7                                              2            14.2           38.298          Only in CB2
  Q9UJ14      GGT7_HUMAN       Glutathione hydrolase 7                                                                  4            11.2           70.466          Only in CB2
  Q5T447      HECD3_HUMAN      E3 ubiquitin-protein ligase HECTD3                                                       2            3.8            97.112          Only in CB2
  Q8IYS2      K2013_HUMAN      Uncharacterized protein KIAA2013                                                         4            11.1           72.68           Only in CB2
  O15162      PLS1_HUMAN       Phospholipid scramblase 1                                                                4            14.8           35.049          Only in CB2
  O14967      CLGN_HUMAN       Calmegin                                                                                 19           45.7           70.038          12388.6
  Q06136      KDSR_HUMAN       3-Ketodihydrosphingosine reductase (KDS reductase)                                       7            32.2           36.187          2214.8
  Q96JJ7      TMX3_HUMAN       Protein disulfide-isomerase TMX3                                                         13           39             51.871          551.6
  Q99720      SGMR1_HUMAN      Sigma non-opioid intracellular receptor 1                                                6            40.4           25.127          370.9
  P16615      AT2A2_HUMAN      Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2)                             44           48.6           114.76          306.2
  P27824      CALX_HUMAN       Calnexin (IP90) (Major histocompatibility complex class I antigen-binding protein p88)   38           57.9           67.567          200.4
  Q8IWV7      UBR1_HUMAN       E3 ubiquitin-protein ligase UBR1                                                         3            2.8            200.21          170.0
  P37268      FDFT_HUMAN       Squalene synthase                                                                        8            24.5           48.115          168.0
  Q99442      SEC62_HUMAN      Translocation protein SEC62                                                              4            10             45.861          164.7
  O43505      B4GA1_HUMAN      Beta-1.4-glucuronyltransferase 1                                                         2            12.8           47.119          161.7
  Q9UBV2      SE1L1_HUMAN      Protein sel-1 homolog 1                                                                  2            6.2            88.754          124.8
  P10586      PTPRF_HUMAN      Receptor-type tyrosine-protein phosphatase F                                             5            4.5            212.88          88.1
  O95260      ATE1_HUMAN       Arginyl-tRNA--protein transferase 1                                                      4            10.2           59.09           87.4
  Q96A33      CCD47_HUMAN      Coiled-coil domain-containing protein 47                                                 11           34.4           55.873          85.3
  O15269      SPTC1_HUMAN      Serine palmitoyltransferase 1                                                            4            11.8           52.743          77.3
  Q4ZIN3      MBRL_HUMAN       Membralin (Transmembrane protein 259)                                                    3            7.3            67.888          62.9
  O43149      ZZEF1_HUMAN      Zinc finger ZZ-type and EF-hand domain-containing protein 1                              5            2.8            331.07          55.5
  Q13501      SQSTM_HUMAN      Sequestosome-1                                                                           6            23.4           47.687          52.7
  O15258      RER1_HUMAN       Protein RER1                                                                             2            15.3           22.958          51.5
  Q9H3N1      TMX1_HUMAN       Thioredoxin-related transmembrane protein 1                                              3            12.9           31.791          42.2
  O00264      PGRC1_HUMAN      Membrane-associated progesterone receptor component 1                                    8            57.4           21.671          40.5
  Q15043      S39AE_HUMAN      Zinc transporter ZIP14 (LIV-1 subfamily of ZIP zinc transporter 4)                       2            6.7            54.212          31.2
  Q8NI60      COQ8A_HUMAN      Atypical kinase COQ8A mitochondrial                                                      3            8.3            71.949          28.5
  P55084      ECHB_HUMAN       Trifunctional enzyme subunit beta mitochondrial                                          15           43.7           51.294          27.8
  P42356      PI4KA_HUMAN      Phosphatidylinositol 4-kinase alpha                                                      2            1.6            231.32          26.3
  O75915      PRAF3_HUMAN      PRA1 family protein 3 (ADP-ribosylation factor-like protein 6-interacting protein 5)     2            16             21.614          25.6
  A1L0T0      ILVBL_HUMAN      Acetolactate synthase-like protein                                                       4            10.9           67.867          23.1
  Q9Y4P3      TBL2_HUMAN       Transducin beta-like protein 2                                                           2            5.6            49.797          22.5
  O60884      DNJA2_HUMAN      DnaJ homolog subfamily A member 2                                                        2            6.8            45.745          22.2
  Q29963      1C06_HUMAN       HLA class I histocompatibility antigen. Cw-6 alpha chain (MHC class I antigen Cw^∗^6)    5            21.9           40.968          21.5
  P20020      AT2B1_HUMAN      Plasma membrane calcium-transporting ATPase 1                                            3            4.2            138.75          21.1
  P49755      TMEDA_HUMAN      Transmembrane emp24 domain-containing protein 10                                         2            12.8           24.976          19.8
  P62341      SELT_HUMAN       Thioredoxin reductase-like selenoprotein T (SelT)                                        2            17.4           22.174          18.8
  P50395      GDIB_HUMAN       Rab GDP dissociation inhibitor beta                                                      2            8.5            50.663          17.0
  P49411      EFTU_HUMAN       Elongation factor Tu mitochondrial (EF-Tu)                                               23           61.5           49.541          15.2
  Q8IXI1      MIRO2_HUMAN      Mitochondrial Rho GTPase 2 (MIRO-2) (hMiro-2)                                            2            4.4            68.117          15.2
  Q14257      RCN2_HUMAN       Reticulocalbin-2                                                                         2            11             36.876          14.6
  Q9BQE3      TBA1C_HUMAN      Tubulin alpha-1C chain (Alpha-tubulin 6)                                                 2            76.2           49.895          12.4
  Q9BXW9      FACD2_HUMAN      Fanconi anemia group D2 protein (Protein FACD2)                                          2            2.3            166.46          12.1
  P04844      RPN2_HUMAN       Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2                 11           37.9           69.283          12.1
  P04843      RPN1_HUMAN       Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1                 19           43             68.569          12.0
  P40939      ECHA_HUMAN       Trifunctional enzyme subunit alpha mitochondrial                                         27           53.1           82.999          12.0
  P39656      OST48_HUMAN      Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit            11           45.2           50.8            11.9
  Q9BVA1      TBB2B_HUMAN      Tubulin beta-2B chain                                                                    3            67.2           49.953          11.5
  Q9BQB6      VKOR1_HUMAN      Vitamin K epoxide reductase complex subunit 1                                            2            19             18.234          11.1
  P13797      PLST_HUMAN       Plastin-3 (T-plastin)                                                                    2            6.3            70.81           11.0
  Q9HCU5      PREB_HUMAN       Prolactin regulatory element-binding protein                                             3            15.1           45.468          10.8
  P07237      PDIA1_HUMAN      Protein disulfide-isomerase (PDI)                                                        2            4.3            57.116          10.3
  P51648      AL3A2_HUMAN      Fatty aldehyde dehydrogenase                                                             6            14.4           57.669          9.9
  P13073      COX41_HUMAN      Cytochrome c oxidase subunit 4 isoform 1 mitochondrial                                   2            13.6           19.576          9.0
  P08195      4F2_HUMAN        4F2 cell-surface antigen heavy chain (4F2hc)                                             3            7              71.122          9.0
  Q15363      TMED2_HUMAN      Transmembrane emp24 domain-containing protein 2 (Membrane protein p24A)                  2            10.9           22.761          8.8
  P61204      ARF3_HUMAN       ADP-ribosylation factor 3                                                                2            18.2           20.601          8.8
  O15173      PGRC2_HUMAN      Membrane-associated progesterone receptor component 2                                    2            18.8           23.818          7.9
  O95831      AIFM1_HUMAN      Apoptosis-inducing factor 1 mitochondrial                                                5            11.1           66.9            6.8
  P00403      COX2_HUMAN       Cytochrome c oxidase subunit 2                                                           3            16.3           25.565          6.1
  P05109      S10A8_HUMAN      Protein S100-A8 (Calgranulin-A)                                                          3            32.3           10.834          6.0
  Q12931      TRAP1_HUMAN      Heat shock protein 75 kDa mitochondrial (HSP 75) (TNFR-associated protein 1)             7            13.2           80.109          5.5
  P22102      PUR2_HUMAN       Trifunctional purine biosynthetic protein adenosine-3                                    4            7.5            107.77          5.4
  O14975      S27A2_HUMAN      Very long-chain acyl-CoA synthetase (VLACS) (VLCS)                                       2            5.5            70.311          5.2
  P11586      C1TC_HUMAN       C-1-Tetrahydrofolate synthase cytoplasmic (C1-THF synthase)                              2            2.7            101.56          5.1
  O75396      SC22B_HUMAN      Vesicle-trafficking protein SEC22b (ER-Golgi SNARE of 24 kDa)                            2            10.2           24.593          5.1
  P30101      PDIA3_HUMAN      Protein disulfide-isomerase A3                                                           5            13.9           56.782          5.1
  P53618      COPB_HUMAN       Coatomer subunit beta (Beta-coat protein)                                                2            2.2            107.14          4.9
  P51571      SSRD_HUMAN       Translocon-associated protein subunit delta (TRAP-delta)                                 2            18.5           18.998          4.8
  P61619      S61A1_HUMAN      Protein transport protein Sec61 subunit alpha isoform 1 (Sec61 alpha-1)                  2            9              52.264          4.6
  P30048      PRDX3_HUMAN      Thioredoxin-dependent peroxide reductase mitochondrial                                   2            9.8            27.692          4.5
  Q7Z6Z7      HUWE1_HUMAN      E3 ubiquitin-protein ligase HUWE1                                                        2            0.5            481.89          4.3
  P50402      EMD_HUMAN        Emerin                                                                                   3            17.3           28.994          4.3
  P24534      EF1B_HUMAN       Elongation factor 1-beta (EF-1-beta)                                                     3            26.7           24.763          4.1
  Q53GQ0      DHB12_HUMAN      Very-long-chain 3-oxoacyl-CoA reductase                                                  4            21.2           34.324          4.0
  Q9P035      HACD3_HUMAN      Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 3                                     9            33.1           43.159          3.8
  Q00325      MPCP_HUMAN       Phosphate carrier protein mitochondrial (Phosphate transport protein) (PTP)              8            28.5           39.958          3.7
  O14980      XPO1_HUMAN       Exportin-1                                                                               5            8.3            123.38          3.7
  P06702      S10A9_HUMAN      Protein S100-A9 (Calgranulin-B)                                                          3            36             13.242          3.7
  Q86VU5      CMTD1_HUMAN      Catechol *O*-methyltransferase domain-containing protein 1                               4            25.2           28.808          3.6
  Q93008      USP9X_HUMAN      Probable ubiquitin carboxyl-terminal hydrolase FAF-X                                     3            1.7            292.28          3.6

All specific interactors are classified by the identification in mass spectrometry data of triplicates by at least two unique peptides. The Uniprot accession numbers with protein name, descriptions and molecular weights are given. Sequence coverage by identified peptides is presented in %. Additionally, the ratio of identification in CB2 expressing cells to control cells was calculated.

Taking those 83 putative interactors we processed a functional protein association network analysis using the STRING online tool ([@B64]) obtaining an interaction network with a protein--protein-interaction enrichment *p*-value \< 1.0e-16. This network consists of 84 nodes (including CB2) and 163 edges with an average node degree of 3.8 and an average local clustering coefficient of 0.392. In the network a significant functional enrichment of proteins involved in protein metabolic process and in response to endoplasmic reticulum (ER) stress were obtained using the GO BP analysis ([Table 3](#T3){ref-type="table"}). These functions are in line with the findings of CC ontology revealing an annotation of ER in 35 CB2 interacting proteins ([Table 3](#T3){ref-type="table"}). Further, the MF gene ontology analysis unveiled an enrichment of proteins with catalytic activity and oxidoreductase activity ([Table 3](#T3){ref-type="table"}). Functional annotations that were used by the STRING database to illustrate interactions network were determined by: text mining, experiments, or databases with a minimum required interaction score of 0.400 ([Figure 2](#F2){ref-type="fig"}). The nodes represent proteins whereas color saturation of the edges mark confidence of the interactions indicating the strength of data support. Several proteins were not connected by any known interactions to the other proteins and are displayed as nodes without any edges. In contrast, some proteins particularly located in the center of the network with many interactions are ER proteins like calnexin and Sec61A1. Also the cargo receptors for GPCR trafficking and resensitization TMED2 and TMED10 have been identified in this network.

###### 

Gene ontology (GO) analysis of 84 CB2 specific interactors (including CB2) using the STRING database (<https://string-db.org/>).

  **Biological process (GO)**                                                                        
  ----------------------------- --------------------------------------------------------------- ---- ----------
  GO:0019538                    Protein metabolic process                                       37   2.8e-05
  GO:0034976                    Response to endoplasmic reticulum stress                        10   2.8e-05
  GO:0044267                    Cellular protein metabolic process                              34   2.8e-05
  GO:0006457                    Protein folding                                                 9    0.000337
  GO:0061024                    Membrane organization                                           16   0.000342
  **Molecular function (GO)**                                                                        
  GO:0003824                    Catalytic activity                                              41   0.000457
  GO:0016491                    Oxidoreductase activity                                         14   0.000457
  GO:0003756                    Protein disulfide isomerase activity                            4    0.00114
  GO:0016408                    C-Acyltransferase activity                                      3    0.0118
  GO:0016509                    Long-chain-3-hydroxyacyl-CoA dehydrogenase activity             2    0.0118
  **Cellular component (GO)**                                                                        
  GO:0042175                    Nuclear outer membrane-endoplasmic reticulum membrane network   31   3.40e-17
  GO:0044432                    Endoplasmic reticulum part                                      29   1.17e-16
  GO:0005789                    Endoplasmic reticulum membrane                                  31   1.17e-16
  GO:0005783                    Endoplasmic reticulum                                           35   4.01e-16
  GO:0031090                    Organelle membrane                                              42   4.50e-13

Displayed are the most significant top five GO pathways in the category Biological Process (BP), Molecular Function (MF), Cellular Component (CC).

![Functional Annotations were used to visualize protein--protein interaction network of 83 identified CB2 interactors by STRING. Illustrated interaction network was determined by text mining, experiments or databases with a minimum required interaction score of 0.400. In this view, the nodes represent proteins and the color saturation of the edges represents the confidence score of data support. CNR2 represents CB2 and SQSTM1 represents p62.](fnmol-12-00224-g002){#F2}

To identify further functional annotations, a systematic analysis of all 83 CB2 interactors was performed using the "DAVID Functional Annotation Tool" ([@B29], [@B30]). The analysis identified 20 clusters with 10 clusters having an enrichment score higher than 2.0 ([Table 4](#T4){ref-type="table"}). The top five of these clusters with a highly significant enrichment (*p* \< 0.0001) in the obtained CB2 interactome ([Table 4](#T4){ref-type="table"}) represent the ER (cluster 1), membrane (cluster 2), oxidoreductase (cluster 3), ER stress and cell redox homeostasis (cluster 4), and lipid metabolism (cluster 5). As the CB2 receptor is expected to interact with nucleotide binding G protein subunits, we screened the functional annotation list with the keyword "nucleotide binding" and identified 13 proteins belonging to this cluster (*p*-value = 5.4 e-2). Out of them five CB2 interactors were enriched for the GOTerm "GTP binding," namely the ADP-ribosylation factor 3 (ARF3), the translation elongation factor TUFM, the member of the Rho family of GTPases RHOT2, and the tubulin chains TUBA1C and TUBB2B (*p*-value of 2.5 e-2).

###### 

Gene ontology (GO) functional annotation clustering.

                                                                                           **Count**   ***p*\_Value**   **FDR**
  ------------------ --------------------------------------------------------------------- ----------- ---------------- ---------
  **Cluster 1**      **Enrichment score: 15.5**                                                                         
  UP_KEYWORDS        Endoplasmic reticulum                                                 34          2.7E-21          3.3E-18
  GOTERM_CC_DIRECT   Endoplasmic reticulum membrane                                        27          3.2E-15          3.8E-12
  UP_SEQ_FEATURE     Topological domain:lumenal                                            18          3.6E-12          4.9E-9
  **Cluster 2**      **Enrichment score: 9.61**                                                                         
  UP_KEYWORDS        Membrane                                                              63          1.3E-12          1.6E-9
  UP_KEYWORDS        Transmembrane helix                                                   54          4.0E-12          5.0E-9
  UP_KEYWORDS        Transmembrane                                                         54          4.6E-12          5.6E-9
  UP_SEQ_FEATURE     Transmembrane region                                                  48          1.1E-9           1.5E-6
  GOTERM_CC_DIRECT   Integral component of membrane                                        50          2.7E-9           3.2E-6
  UP_SEQ_FEATURE     Topological domain:cytoplasmic                                        33          3.1E-6           4.3E-3
  **Cluster 3**      **Enrichment score: 3.59**                                                                         
  UP_KEYWORDS        Oxidoreductase                                                        12          2.1E-5           2.6E-2
  GOTERM_BP_DIRECT   Oxidation--reduction process                                          12          7.7E-5           1.1E-1
  GOTERM_MF_DIRECT   Oxidoreductase activity                                               7           3.7E-4           4.7E-1
  UP_KEYWORDS        NADP                                                                  5           6.8E-3           8.1E0
  **Cluster 4**      **Enrichment score: 3.17**                                                                         
  UP_KEYWORDS        Redox-active center                                                   7           4.4E-8           5.4E-5
  GOTERM_BP_DIRECT   Response to endoplasmic reticulum stress                              6           2.4E-5           3.4E-2
  GOTERM_BP_DIRECT   Cell redox homeostasis                                                6           2.7E-5           3.9E-2
  INTERPRO           Thioredoxin domain                                                    5           3.0E-5           3.9E-2
  INTERPRO           Thioredoxin, conserved site                                           4           5.2E-5           6.8E-2
  GOTERM_MF_DIRECT   Protein disulfide isomerase activity                                  4           1.5E-4           1.9E-1
  INTERPRO           Thioredoxin-like fold                                                 6           2.6E-4           3.4E-1
  GOTERM_CC_DIRECT   Cell                                                                  5           1.1E-3           1.3E0
  UP_SEQ_FEATURE     Short sequence motif:prevents secretion from ER                       4           2.1E-3           2.8E0
  GOTERM_MF_DIRECT   Isomerase activity                                                    3           4.4E-3           5.4E0
  UP_SEQ_FEATURE     Domain:thioredoxin                                                    3           8.2E-3           1.1E1
  UP_KEYWORDS        Isomerase                                                             3           8.7E-2           6.7E1
  UP_SEQ_FEATURE     Disulfide bond                                                        14          4.3E-1           1.0E2
  UP_KEYWORDS        Disulfide bond                                                        13          7.5E-1           1.0E2
  **Cluster 5**      **Enrichment score: 2.87**                                                                         
  GOTERM_MF_DIRECT   Long-chain-3-hydroxyacyl-CoA dehydrogenase activity                   3           6.6E-5           8.3E-2
  UP_KEYWORDS        Lipid metabolism                                                      9           3.6E-4           4.4E-1
  KEGG_PATHWAY       Fatty acid elongation                                                 4           5.4E-4           5.8E-1
  KEGG_PATHWAY       Fatty acid metabolism                                                 4           3.6E-3           3.8E0
  KEGG_PATHWAY       Biosynthesis of unsaturated fatty acids                               3           9.6E-3           9.9E0
  UP_KEYWORDS        Fatty acid metabolism                                                 4           1.4E-2           1.6E1
  **Cluster 6**      **Enrichment score: 2.56**                                                                         
  GOTERM_CC_DIRECT   Mitochondrial inner membrane                                          9           8.2E-4           9.8E-1
  UP_SEQ_FEATURE     Transit peptide:mitochondrion                                         9           8.5E-4           1.2E0
  UP_KEYWORDS        Transit peptide                                                       9           1.4E-3           1.7E0
  UP_KEYWORDS        Mitochondrion inner membrane                                          6           4.7E-3           5.7E0
  GOTERM_CC_DIRECT   Mitochondrion                                                         14          6.3E-3           7.2E0
  UP_KEYWORDS        Mitochondrion                                                         11          1.4E-2           1.6E1
  **Cluster 7**      **Enrichment score: 2.54**                                                                         
  GOTERM_BP_DIRECT   Protein folding                                                       7           1.8E-4           2.5E-1
  UP_KEYWORDS        Chaperone                                                             5           8.9E-3           1.0E1
  GOTERM_MF_DIRECT   Unfolded protein binding                                              4           1.5E-2           1.8E1
  **Cluster 8**      **Enrichment score: 2.38**                                                                         
  GOTERM_CC_DIRECT   Endoplasmic reticulum-Golgi intermediate compartment                  6           1.4E-5           1.6E-2
  GOTERM_BP_DIRECT   Retrograde vesicle-mediated transport, Golgi to ER                    6           3.7E-5           5.2E-2
  UP_KEYWORDS        ER-Golgi transport                                                    6           3.9E-5           4.8E-2
  GOTERM_CC_DIRECT   ER to Golgi transport vesicle membrane                                4           1.7E-3           2.0E0
  GOTERM_BP_DIRECT   COPII vesicle coating                                                 4           2.8E-3           3.9E0
  UP_KEYWORDS        Protein transport                                                     9           3.2E-3           3.8E0
  GOTERM_CC_DIRECT   Golgi membrane                                                        9           5.1E-3           5.9E0
  GOTERM_BP_DIRECT   ER to Golgi vesicle-mediated transport                                5           6.3E-3           8.6E0
  GOTERM_CC_DIRECT   Transport vesicle                                                     4           9.0E-3           1.0E1
  GOTERM_CC_DIRECT   Golgi apparatus                                                       10          1.5E-2           1.7E1
  GOTERM_CC_DIRECT   Endoplasmic reticulum-Golgi intermediate compartment membrane         3           3.4E-2           3.4E1
  UP_KEYWORDS        Golgi apparatus                                                       8           4.5E-2           4.4E1
  GOTERM_BP_DIRECT   Transport                                                             5           7.6E-2           6.7E1
  GOTERM_BP_DIRECT   Intracellular protein transport                                       4           9.4E-2           7.6E1
  UP_KEYWORDS        Cytoplasmic vesicle                                                   5           1.4E-1           8.3E1
  **Cluster 9**      **Enrichment score: 2.32**                                                                         
  UP_KEYWORDS        Lipid metabolism                                                      9           3.6E-4           4.4E-1
  UP_KEYWORDS        NADP                                                                  5           6.8E-3           8.1E0
  UP_KEYWORDS        Steroid biosynthesis                                                  3           8.8E-3           1.0E1
  UP_KEYWORDS        Lipid biosynthesis                                                    4           2.5E-2           2.7E1
  **Cluster 10**     **Enrichment score: 2.11**                                                                         
  GOTERM_MF_DIRECT   Dolichyl-diphosphooligosaccharide-protein glycotransferase activity   3           7.8E-4           9.8E-1
  GOTERM_CC_DIRECT   Oligosaccharyltransferase complex                                     3           8.8E-4           1.0E0
  GOTERM_BP_DIRECT   Protein N-linked glycosylation via asparagine                         3           1.4E-2           1.9E1
  KEGG_PATHWAY       *N*-Glycan biosynthesis                                               3           4.0E-2           3.6E1
  UP_KEYWORDS        Glycosyltransferase                                                   4           7.0E-2           5.9E1

After analyzing 84 CB2 specific interacting proteins (including CB2) with DAVID (

https://david.ncifcrf.gov/home.jsp

) 20 clusters were identified of which 10 were represented in this table with an enrichment score \>2.

Furthermore, we identified six proteins that were only expressed in the stable Strep-HA-CB2-HEK293 cells; the delta(24)-sterol reductase (DHC24), dehydrogenase/reductase SDR family member 7 (DHRS7), glutathione hydrolase 7 (GGT7), E3 ubiquitin-protein ligase HECTD3 (HECD3), an uncharacterized protein KIAA2013 (K2013), and the phospholipid scramblase 1 (PLS1).

P62 Is an Interaction Partner of Cannabinoid Receptor CB2 {#S3.SS2}
---------------------------------------------------------

To verify the experimental approach and the obtained interactome list, we selected one specific protein with a high probability of interaction. To increase the likelihood of a direct protein interaction with CB2, this candidate should have a relatively low number of edges in our STRING network ([Figure 2](#F2){ref-type="fig"}). Furthermore, the candidate should represent a signaling hub protein that might be involved in receptor and signaling crosstalk. Therefore, we chose p62/SQSTM1 for further experiments. The scaffold protein p62 is included in the 34 proteins of the functional annotation cluster 1 representing ER association. It is involved in TNF receptor signaling ([@B33]) and in the development of PDB ([@B39]) and functions as a signaling hub and as an autophagy adaptor ([@B32]). The identification of p62 based on six specific tryptic peptides (i.e., AGEARPGPTAESASGPSEDPSVNFLK, CSVCPDYDLCSVCEGK, DHRPPCAQEA-PR, LTPVSPESSST EEK, NMVHPNVICDGCNGPVVGTR, NYDIGAALDTIQYSK) that represent 23.4% of the whole protein sequence ([Figure 3A](#F3){ref-type="fig"}). Indeed, the quantification ratio of CB2 stable expressing versus control cells showed that p62 specific peptides were identified 52 times more in CB2-cells than in controls ([Table 2](#T2){ref-type="table"}).

![**(A)** Protein sequence of p62 with protein domains underlaid in light blue boxes (Phox and Bem1p domain (PB1), Zinc finger-type (ZZ), TNF receptor-associated factor 6 (TRAF6), LC3-interacting region (LIR), protein sequence rich in proline (P), glutamic acid (E), serine (S), and threonine (T) (PEST), UBA. The six peptides identified after tryptic digestion by mass spectrometry are highlighted in red and blue. **(B)** Verification of the interaction of CB2 receptors with p62 by co-immunoprecipitation (Co-IP) of transiently overexpressed flag tagged CB2 receptors (FL-CB2) with endogenously expressed p62 in HEK293 cells. The precipitated p62 protein intensity directly correlated with the amount of transfected CB2-receptor plasmid (either 1 or 2 μg) that was not influenced by 10 min stimulation with the CB2 agonist HU-210. Representative result of *n* \> 3.](fnmol-12-00224-g003){#F3}

In the next step, we verified the physical interaction of CB2 receptors with p62 by co-immunoprecipitation ([Figure 3B](#F3){ref-type="fig"}). To this end we generated a Flag-tagged CB2 receptor using the expression vector pcDNA3.1 and transiently transfected HEK293 cells. We precipitated CB2 using beads carrying FLAG M2 antibodies and detected endogenous p62 by using an antibody against the human p62 protein ([Figure 3B](#F3){ref-type="fig"}). The endogenous p62 was co-precipitated in Flag-tagged CB2-transfected (FL-CB2) cell extracts in an intensity directly correlated with the amount of transfected CB2-receptor plasmid (either 1 or 2 μg). In all pre-IP extracts (input) p62 was detectable in comparable intensities whereas in control transfected protein extracts (pcDNA3.1) no p62 band was visible after immunoprecipitation. The stimulation with a CB2 receptor agonist (HU-210) did not alter the interaction ([Figure 3B](#F3){ref-type="fig"}). These results strongly indicate that CB2 receptor interacts with p62 and that stimulation of CB2 does not interfere with this interaction.

CB2 Receptors Colocalize With p62 Vesicles Mainly in Plasma Membrane Associated Regions {#S3.SS3}
---------------------------------------------------------------------------------------

Once activated, GPCRs are typically internalized and either degraded or recycled to the membrane for another activation cycle. Degradation can occur via lysosome and autophagy pathways where the scaffolding protein p62 is involved in. Since we showed that CB2 interacts with p62 in whole cell lysates we wondered at which cellular compartment this interaction is taking place. We performed immunocytochemical studies of HEK293 cells expressing endogenously p62 and transiently CB2. For surface membrane staining we used WGA-texas red labeled probes. Confocal microscopy revealed a broad and predominant membrane localization of transiently expressed CB2 receptors ([Figure 4](#F4){ref-type="fig"} and [Supplementary Figure 2](#FS1){ref-type="supplementary-material"}) but a localization of p62 in dotted and vesicular like structures that are most probable lysosome and autophagosome areas. Because of the relatively strong heterologous expression of CB2 we selected the p62 positive areas and analyzed the co-localization with CB2 receptors using the Manders coefficient and obtained a mean value of 0.46 ± 0.07. Additionally, we aimed to better visualize and to clearly distinguish localizations of both proteins in co-localization with the membrane marker. Therefore, we performed a 3D reconstruction modeling of confocal images. With this approach we remodeled the p62 expression in red vesicular structures ([Figures 4D--G](#F4){ref-type="fig"}). We used for our analysis a segmentation algorithm that eliminates signals below a threshold to visualize the p62 vesicles optimally. Thus, any signals of p62 that are weaker are not present in the 3D-reconstruction images. In white/gray we visualized the areas that were positively stained with membrane marker ([Figures 4D,F](#F4){ref-type="fig"}) that intermingled with green CB2 receptor signals ([Figures 4D,E](#F4){ref-type="fig"}). Our 3D reconstruction images indicated that those p62 vesicles were surrounded by CB2 positive areas that were adjacent to the surface membrane ([Figure 4D](#F4){ref-type="fig"}). These results demonstrate that about half of the p62 positive areas co-expressed CB2 and that these p62-CB2 vesicles are at the cell membrane.

![**(A--G)** Confocal light microscopy of HEK293 cells transiently expressing CB2 receptors. **(A)** Immunohistochemical staining of CB2 (green), p62 (red), and DAPI (blue). The membrane was stained by Texas-red conjugated wheat-germ-agglutinin (white) and DAPI revealed the localization of the nucleus. **(B--G)** 3D reconstruction modeling of confocal images using a segmentation algorithm to distinguish single signal from different channels. **(D--G)** Higher zoom in of 3D reconstructed cell showing a strong overlap of CB2 positive areas with the membrane marker (white). P62 was found in vesicular like structures that intermingled with membranal CB2 positive areas (yellow arrows).](fnmol-12-00224-g004){#F4}

Intracellular Regions of CB2 Receptor Are Not Responsible for the Interaction With p62 {#S3.SS4}
--------------------------------------------------------------------------------------

Since p62 is localized intracellularly we wondered whether p62 interacts with intracellular domains of CB2. We designed expression constructs deleting the three intracellular loops and the C-terminus of the CB2 receptor ([Figure 5A](#F5){ref-type="fig"}). Surprisingly none of these deletion constructs altered the interaction of CB2 with p62 in co-IP studies if correlated to the different expression levels in the input and the IPs ([Figure 5B](#F5){ref-type="fig"}). We conclude from this experiment that it is not individual intracellular loops that are responsible for the interaction, but rather that multiple domains are involved in the interaction with p62. Because receptor structure is strongly dependent on the transmembrane domains, we have not investigated further deletion constructs of CB2 in this assay.

![**(A)** Schematic drawing of CB2 receptor protein with extracellular N-terminus and three extracellular loops (e1, e2, e3), seven transmembrane domains, and three intracellularly localized loops (i1, i2, i3) and the C-terminus. The red marked intracellular regions were deleted in CB2 expression plasmids and used for following Co-IP studies. **(B)** Representative Western blot results of CB2 precipitations using Flag antibody with lysates of HEK293 cells transiently transfected with p62-WT (1 μg) and Flag-CB2 constructs with the respective deletions (ΔC-CB2, Δ i1-CB2, Δ i2-CB2, Δ i3-CB2). Considering lower expression levels of deletion constructs compared to WT-full length Flag-CB2, the co-precipitated p62 protein levels were similar in all approaches. The IP figure was grouped from cropped parts of the same gels/blots indicated by the border line. This experiment has been performed at least two times independently.](fnmol-12-00224-g005){#F5}

ZZ Domain of p62 Is Important for Interaction With CB2 {#S3.SS5}
------------------------------------------------------

P62 is a cargo and multifunctional protein carrying several motifs and domains responsible for the interaction with a variety of proteins ([@B47]). Therefore, we aimed to identify the motif responsible for CB2 interaction and co-expressed CB2 with deletion constructs of p62 lacking the PB1 domain and the binding motifs ZZ and UBA respectively ([Figure 6A](#F6){ref-type="fig"}). Only the ZZ deletion construct failed to co-precipitate CB2 indicating that this region is important for the interaction of p62 with CB2 ([Figure 6B](#F6){ref-type="fig"}). All other investigated p62 constructs including the UBA-domain deletion protein resulted in CB2 receptor co-precipitations that were comparable to positive controls. We therefore showed that CB2 interacts with p62 via the ZZ-domain.

![**(A)** Schematic illustration of Flag-p62 deletion constructs for ZZ, PEST, and UBA motifs that were used for following co-immunoprecipitation experiments to identify interaction region. **(B)** Stably expressing HA-CB2 HEK293 cells were transiently transfected with different Flag-p62-deletion constructs, respectively. Protein extracts were used for precipitation of Flag-p62 using Flag antibody. The expression levels in input samples for CB2 and p62 were comparable in all constructs. Immunoprecipitation result of Flag-p62 ΔZZ revealed a significantly reduced coprecipitation of CB2 indicating that this domain in p62 is involved in the interaction with CB2. Representative results of three independent experiments were presented.](fnmol-12-00224-g006){#F6}

In summary, we identified the CB2 interactome in HEK293 cells consisting of 83 interacting proteins involved in, e.g., biosynthesis, trafficking, and signaling. The identified proteins are mainly localized at the ER and other membrane structures in the cell and in intracellular compartments. The autophagy receptor p62 was identified by six unique peptides as an interactor with a very high probability of interaction with CB2 receptor. In our investigations we focused on p62-CB2 complex formation and could verify that CB2 receptor interacts with the ZZ domain of p62 at membranous structures close to the cell surface. Future investigations will concentrate on the characterization of the interaction and its physiological impact in the cell.

Discussion {#S4}
==========

Investigations to identify GPCR interactomes are valuable approaches for the understanding of receptor function and methods like AP-MS and MYTH enabled first reproducible identifications of GPCR interactomes ([@B34]; [@B62]). In the present work we applied tandem mass spectrometry and identified a CB2 receptor interactome consisting of 83 proteins and characterized its interaction with p62 in more detail. The identified interactome especially contains protein networks involved in signaling, biosynthesis and trafficking like calnexin, tubulin chains, and TMED10.

One major concern in the investigations of protein interactomes is the reduction of false-positive findings, which we minimized by the inclusion of only those proteins that were identified by at least two unique peptides. To further drastically reduce the false discovery rate a method established by [@B24] was applied and analyzed the CB2 receptor interactome in triplicates with a reproducibility of at least 90%. Thus, the identified interaction data in our study should represent data with a high level of robustness and reliability. The lack of specific CB2 antibodies ([@B9]) limited our experimental set up to cultured model cells reconstituted with an epitope- tagged CB2 receptor. But the Flp-mediated recombination enabled an insertion of CB2 receptor cDNA into a single genomic locus, which minimize the overexpression levels in this model system. Nevertheless, the relatively high biosynthesis of the CB2 protein could be represented in the interaction network, since GO annotation analysis showed that a relatively high portion of the CB2 interacting proteins were associated with ER and with proteins involved in biosynthesis and degradation pathways. Sec61A1, calnexin, and DNAJA2 are examples for interactors that are functionally relevant in translocation of newly synthesized polypeptides to the ER, correct folding and further trafficking of proteins. Previously, binding of calnexin to the GPCRs rhodopsin and delta-opioid receptor and an interaction of the chaperone of the J protein family DNAJ2B to rhodopsin had been demonstrated ([@B11]; [@B57]; [@B66]) emphasizing the relevance of our investigations.

The identified GTP binding proteins are involved in a variety of functions ranging from recycling and trafficking to microtubule stability, cytokinesis, and mitochondrial biosynthesis. The signaling alpha subunits of guanine nucleotide-binding proteins (GNA proteins) were also identified in the list of interacting proteins. Interestingly, GNAS1 and the GNAI3 proteins were present by a single unique peptide but not GNAI1 or GNAI2. The CB2 receptor has mainly been associated with G alpha-i subunit coupled responses and signaling via G alpha s coupled subunits has, to our knowledge, not been reported for CB2 signaling. Possibly, our results hint to similar options of CB2 receptor signaling via GNAS and GNAI3 as has already been described for CB1 receptor ([@B48]; [@B21]).

Findings for other GPCRs further support our newly identified interactions of CB2 receptors. For example, a direct interaction of the C-terminus of alpha2B-adrenergic receptor (alpha2B-AR) with tubulin has been demonstrated to mediate receptor trafficking from ER to cell surface ([@B18]). Our findings of an interaction of CB2 with the tubulin chains, TUBB2B and TUBA1C, might implicate a similar role for proper receptor transport. In line with this, the interactions with the trafficking proteins, TMED2 and TMED10, might hint at an endocytic transport of resensitized CB2 receptor via these proteins as has already been demonstrated for opioid receptor OPRM1 and purinergic nucleotide receptor P2RY4 ([@B43]). Our results open the path for future studies to investigate, e.g., if CB2 receptor trafficking and homeostasis is coordinated by its newly identified interacting proteins.

Those six proteins that were only identified in CB2-expressing cells DHC24, DHRS7, GGT7, HECD3, KIAA2013, and PLS1 are not forming an interaction network. Nevertheless, the interaction of CB2 with DHC24, a sterol intermediate catalyzing enzyme, and PLS1, an enzyme that flips phosphatidylserines between membrane leaflets, strongly argues for a functional importance in metabolism of lipid molecules connected to the cell membrane that might be of importance, e.g., for viral entry ([@B67]; [@B12]).

The reliability of our data is supported by the fact that we have analyzed one protein by Co-IP and could verify the results obtained by the AP-MS approach. For the detailed interaction analysis, we focused on the scaffold protein p62. Our results show a localization of CB2 at p62 positive vesicles that are also WGA positive. WGA selectively binds to *N*-acetylglucosamine and *N*-acetylneuraminic acid (sialic acid) residues at the cell membrane ([@B68]). Because of the threshold that we used for 3D-reconstructions, the amount of p62 proteins cannot be compared between the models of confocal images and Western blots.

The protein p62 acts as a cargo protein in autophagy and proteasome targeting by its UBA and PB1 domain ([@B13]) and regulates the activation of NF-κB ([@B59]). We identified the ZZ domain as a main contributor to the interaction with CB2. Recently, binding of the ZZ domain of p62 to arginylated BiP (the ER-localized homolog of Hsp70) was demonstrated to be involved in p62 oligomerization and interaction with the autophagy marker LC3 leading to p62 targeting to autophagosomes and selective lysosomal co-degradation of R-BiP and p62 together with associated cargoes ([@B10]). The enzyme responsible for the N-terminal arginylation is catalyzed by arginyltransferase 1 (ATE1)-encoded Arg-transfer RNA transferases ([@B10]), which was also identified in the CB2 interactome. Therefore, the ZZ domain is particularly important for redirecting N-end rule substrates to the autophagy pathway ([@B37]). Thus, biologically the p62-CB2-interaction could be of relevance in cells for an autophagosomal degradation and clearance of CB2 receptors. However, the interaction via the ZZ-type zinc finger motif of p62 also hints at a signaling complex formation as, e.g., the binding to RIP1 protein that links PKCz to form a signaling complex ([@B20]; [@B41]). RIP1 kinase binds to TNF receptor influencing NF-κB and p38 MAPK signaling pathways ([@B41]), which are also activated by CB2 receptor expression or activation ([@B16]; [@B65]). Generally, CB2 receptor functions are connected to co-stimulatory effects of, e.g., cytokines, which are then modulated by the GPCR action ([@B5]). Because dysfunction of p62 as well as CB2 receptors are involved in neurodegenerative diseases, inflammation, cancer and bone biology ([@B51]; [@B17]; [@B58]), it has to be clarified in future experiments if the complex formation of p62 and CB2 is involved in these pathophysiologic functions. Since p62 acts as a signaling platform for, e.g., TNF receptor 1, IL-1 receptor, and RANK receptor ([@B47]) and is involved in Toll-like receptor 4 (TLR4) -- mediated autophagy ([@B22]), our findings might indicate that this platform could function as a signaling hub, which enables the crosstalk of different receptors with CB2 protein. Recently identified interaction between CB2 and TLR4 and their co-expression, co-precipitation and co-functioning in macrophage activation and cancer progression ([@B69]) might be one possible example for these protein complexes.

In general, the CB2 receptor is emerging as an attractive therapeutic target for immunomodulation ([@B6]). The potential of CB2 antagonists as a target for treating cancer ([@B69]) and liver fibrosis ([@B44]) and of CB2 receptor agonists in the treatment of neuropathic pain, neuroinflammation, and neurodegenerative disorders ([@B26]; [@B42]; [@B55], [@B56]; [@B14]) hint to the need of molecular insights into the activation mechanism of CB2.

Recently, the crystal structure of the human CB1 and CB2 receptors have been revealed ([@B28]; [@B36]; [@B40]) and led to the discovery of an opposing functional profile of CB2 antagonism versus CB1 agonism ([@B40]). The clarification of ligand selectivity or function will provide new insights into precise modulation of the ECS by structural analysis, molecular docking and mutagenesis studies ([@B40]). A combination of crystal structure data with results from protein interactome screenings will contribute to facilitate rational drug design and understand mode of action of agonists or antagonists/inverse agonists. Our data add a first step toward this aim, but in future it would be of additional relevance to investigate the CB2 interactome by applying a broader spectrum of cannabinoids.

Despite the use of a heterologous expression system in HEK293 cells, the present work reveals for the first time a CB2 interactome and represent a basal and representative overview. HEK293 cells have been shown to express a variety of GPCR class A transcripts like histamine, dopamine, chemokine, and adenosine receptors ([@B2]). Thus, the machinery for GPCR biosynthesis, signaling, and trafficking is present in these cells and is available for the over-expressed cannabinoid receptors that are functional in HEK293 cells ([@B49]; [@B31]). Nevertheless, investigations of native CB2 expressing cells like lymphocytes and macrophages might result into partially different interactomes. It will therefore be valuable to perform similar screening approaches in different cell types under stimulation with different ligands and systematically compare the interactomes to get a specific and detailed understanding of the CB2 receptor function.

In summary, with the identification of new protein interaction partners for CB2, our findings provide new molecular insights contributing for a better understanding of CB2 receptor biosynthesis, signaling and functions that might account to improve therapeutic strategies of this clinically relevant protein.
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AOBS

:   Acusto Optic Beam Splitter

AP-MS

:   affinity purification coupled to mass spectrometry

BP

:   biological process

CB1

:   cannabinoid receptor 1

CB2

:   cannabinoid receptor 2

CC

:   cellular component

DDM

:   dodecylmaltosid

DMEM

:   Dulbecco's modified Eagle's medium

FBS

:   fetal bovine serum

FCS

:   fetal calf serum

GPCRs

:   G-protein coupled receptors

HyD

:   high sensitive hybrid detectors

LPS

:   lipopolysaccharide

MF

:   molecular function

MYTH

:   modified membrane yeast to hybrid

NF- κ B

:   nuclear factor- light-chain-enhancer of activated B cells

PDB

:   Paget's disease of bone

RANK

:   receptor activator of nuclear factor-kappa B

RANKL

:   receptor activator of nuclear factor-kappa B ligand

RT

:   room temperature

TLRs

:   toll like receptors

TNF

:   tumor necrosis factor

TRAF6

:   TNF-receptor associated factor 6

TUBA1C

:   tubulin alpha-1C

TUBB2B

:   tubulin beta-2B

UBA

:   ubiquitin-associated domain

WGA

:   wheat germ agglutinin.
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